[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100631371":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":33,"locations":40,"responsibleParty":60,"collaborators":26,"id":64,"slug":26,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":67,"acronym":26,"eligibilityCriteria":68,"healthyVolunteers":65,"sex":69,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":26,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":26,"overallStatus":43,"whyStopped":26,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Beni-Suef University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"(control)","ACTIVE_COMPARATOR","Patients received estradiol valerate 2 mg. in form of (Cycloprogynova® Bayer Shering Pharma) white pills starting dose is one pill T.I.D may be increased to two pills T.I.D according to endometrial thickness in day 9 measured by vaginal ultrasound.",[13],"Drug: estradiol valerate 2 mg",{"label":15,"type":16,"description":17,"interventionNames":18},"tadalafil 5 mg","EXPERIMENTAL","once daily in form of (tadanerfi 5® Nerhadou international5 co.) daily in addition to the above treatment protocol from the first day of the cycle until the day of starting progesterone",[19],"Drug: Tadalafil 5mg",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Tadalafil 5mg","phosphodiesterase type 5 (PDE-5) inhibitor",[15],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"estradiol valerate 2 mg","estradiol valerate 2 mg. in form of (Cycloprogynova® Bayer Shering Pharma) white pills starting dose is one pill T.I.D may be increased to two pills T.I.D according to endometrial thickness in day 9 measured by vaginal ultrasound.",[9],[32],"Cycloprogynova®",[34],{"name":35,"role":36,"phone":37,"phoneExt":38,"email":39},"Sara A Salem","CONTACT","01272842226","02","sara.abdalla@med.bsu.edu.eg",[41],{"facility":42,"status":43,"city":44,"state":45,"zip":46,"country":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Beni-suef university Hospital","RECRUITING","Banī Suwayf","Beni Suweif Governorate","62521","Egypt",{"type":49,"coordinates":50},"Point",[51,52],31.09785,29.07441,{"lat":52,"lon":51},[55],{"name":56,"role":36,"phone":57,"phoneExt":58,"email":59},"Beni Suef University","082 2356845","2","info@bsu.edu.eg",{"type":61,"investigatorFullName":62,"investigatorTitle":63,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Sara Abdallah Mohamed Salem","Associate Professor of obstetrics and gynecology","100631371",false,"NCT07499804","Effect of Tadalafil on Endometrial Thickness and Frozen Embryo Transfer Outcomes","Inclusion Criteria:\n\n* has good quality day five frozen embryos.\n\nExclusion Criteria:\n\n* hypotension (blood pressure less than 90\u002F50) and\n* history of stroke or myocardial infarction","FEMALE","18 Years","43 Years",{"count":73,"type":74},100,"ESTIMATED","INTERVENTIONAL",[77],"PHASE4","investigate the effect of different vasodilators as Tadalafil in women with unexplained infertility using IVF",[80,81],"IVF","Infertility, Female","2026-03-25",{"date":84,"type":85},"2026-03-30","ACTUAL",{"date":87,"type":85},"2023-10-01",{"date":89,"type":74},"2026-04-30",{"name":5,"class":6},1]